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MYRIAD AFTER MYRIAD: THE PROPRIETARY DATA DILEMMA
John M. Conley,* Robert Cook-Deegan** &
Gabriel Ldzaro-Muiioz***
Myriad Genetics' long-time monopoly on BRCA gene testing
was significantly narrowed by the Supreme Court's decision in
Association of Molecular Pathology v. Myriad Genetics, Inc., and
will be further narrowed in the next few years as many of its still-
valid patents expire. But these developments have not caused the
company to acquiesce in competition. Instead, it has launched a
litigation offensive against a number of actual and potential
competitors, suing them for infringement of numerous unexpired
patents that survived the Supreme Court case.
A parallel strategy may have even greater long-term
significance, however. In announcing expanded operations in
Europe, Myriad has emphasized that it will rely less on patents and
more on its huge proprietary database of genetic mutations and
associated health outcomes-a strategy that could be used in the
United States as well. Myriad has built that database over its many
years as a patent-based monopolist in the BRCA testing field, and
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has not shared it with the medical community for more than a
decade. Consequently, Myriad has a unique ability to interpret the
health significance of patients' genetic mutations, particularly in
the case of rare "variants of unknown significance."
This Article reviews the current state of Myriad's patent
portfolio, describes its ongoing litigation offensive, and then
analyzes its proprietary database strategy. The Article argues that
Myriad's strategy, while legally feasible, undercuts important
values and objectives in medical research and health policy. The
Article identifies several ways in which the research and health
care communities might fight back, but acknowledges that it will
be a difficult uphillfight.
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I. INTRODUCTION
In the summer of 2013, the Supreme Court's decision in
Association for Molecular Pathology v. Myriad Genetics'
("Myriad") took a significant bite out of Myriad Genetics' patent
portfolio. Now, almost a year later, the inexorable process of
patent expiration is poised to take an even bigger bite. The
invalidation of surviving patents in ongoing litigation-most of it
started by Myriad-poses yet another threat.
But Myriad is not waving a white flag. On the contrary, the
company is on the offensive. In the United States, it has sued
almost every competitor that has sprung up in response to the
Supreme Court's decision invalidating its genomic DNA patents.
In Europe, where its patents have been more limited in scope,
Myriad has opened a major new testing laboratory with more
investment promised. Investor response has been steady: while
Myriad's stock fell with the rest of the market after the 2008
financial crisis, it was not significantly affected by the Supreme
Court's decision and, as of April 7, 2014, is trading at a post-crash
high.2
What lies behind Myriad's confidence and the apparent support
of its stockholders? Part of the answer may be a genuine belief in
the strength and economic significance of its surviving patents as
well as in the superiority of its testing services. A more likely
answer, however, is that Myriad has an ace up its sleeve. During its
years of patent-based monopoly in the market for testing the
BRCA 1 and 2 genes, which are associated with susceptibility to
breast and ovarian cancer, Myriad has built up an immense
proprietary database. 3 Myriad's unparalleled array of data
correlating gene mutations with health outcomes, family histories,
and other phenotypic factors gives it a unique ability to interpret
BRCA gene test results, especially those that yield ambiguous
1133 S. Ct. 2107 (2013).
2 See MYRIAD GENETICS, INC., http://finance.yahoo.com/q/hp?s=MYGN&a=
03&b=7&c=2014&d=03&e=7&f=2014&g=d (last visited Apr. 7, 2014).
3 See John M. Conley, Dan Vorhaus & Robert Cook-Deegan, How Will
Myriad Respond to the Next Generation of BRCA Testing?, GENOMICS L. REP.
(Mar. 1, 2011), http://www.genomicslawreport.com/index.php/2011/03/01/how-
will-myriad-respond-to-the-next-generation-of-brca-testing/.
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findings, or variants of unknown significance ("VUS"). This
advantage will long outlive the expiration and invalidation of
Myriad's remaining patents.
Myriad's proprietary database gives it a key competitive
advantage in breast and ovarian cancer risk prediction. As
personalized medicine continues to grow and the market for
personal health risk prediction expands, more companies will
create proprietary databases containing information about genes
and other biomarkers. Whether clinical data should be protected as
trade secrets, despite the fact that access to this information can
have important health consequences for individual patients, is a
profound ethical and legal dilemma.
The purpose of this Article is to explore the legal, business,
scientific, and policy ramifications of Myriad's database. Part II
reviews the state of Myriad's patent portfolio after the Supreme
Court's decision, while Part III describes Myriad's post-Myriad
patent litigation offensive. Part IV presents a detailed analysis of
Myriad's apparent plan to maintain its database as a proprietary
asset, including a consideration of the relevant trade secret law.
Part V describes several ongoing third-party efforts to replicate
Myriad's database and assesses their prospects for success. Part VI
concludes by addressing the ultimate policy questions of whether
Myriad should and could be compelled to share its data.
II. THE STATE OF MYRIAD'S PATENT PORTFOLIO
On June 13, 2013, the Supreme Court decided Myriad.4
Partially reversing the Federal Circuit,' it held unanimously that
genomic DNA ("gDNA") merely isolated from the human body is
not patent-eligible (or "statutory") subject matter under Section
101 of the Patent Act,6 but complementary DNA ("cDNA"), which
is synthesized in a lab and lacks the non-coding regions present in
naturally occurring gDNA, is.7 The Court did not review the
4 133 S. Ct. 2107 (2013).
' Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 689 F.3d 1303
(Fed. Cir. 2012).
6 35 U.S.C. § 101 (2012).
7 Myriad, 133 S. Ct. at 2011.
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portions of the Federal Circuit's ruling that dealt with the statutory
subject matter status of Myriad's method claims. The lower court
had invalidated claims to methods for "comparing" a patient's
DNA at the BRCA gene to a normal, or wild-type sequence, while
upholding a claim to a method of assessing the efficacy of a drug
by growing a cell with a cancer-predisposing mutation in the
presence and absence of the drug.'
Together, the Federal Circuit and Supreme Court invalidated
only ten product and method claims out of Myriad's vast patent
portfolio. The company's post-decision press release stressed that
it still has "more than 500 valid and enforceable claims in 24
different patents conferring strong patent protection for its
BRACAnalysis test."9 Claims to cDNA, primers, and various
testing and diagnostic methods were unaffected.10 On the other
side, however, even the cDNA claims that the Supreme Court
expressly approved and the method claim upheld by the Federal
Circuit" have survived only the preliminary test of patentable
subject matter. Those claims (and all others in Myriad's portfolio)
remain subject to challenge-indeed, a credible challengel2 -on
grounds of novelty (Section 102),13 obviousness (Section 103),14
and failure to satisfy Section 112's written description
8Myriad, 689 F.3d at 1303.
9 Company Statement, Myriad Genetics, Supreme Court Upholds Myriad's
cDNA Patent Claims (June 13, 2013), available at https://www.myriad.com/
about-myriad/media-center/supreme-court-upholds-myriads-claims/. In addition,
the Federal Circuit invalidated five method claims, a decision that was not
reviewed by the Supreme Court. These claims were drawn to methods of
comparing or analyzing BRCA gene sequences. Myriad, 689 F.3d at 1335.
10 These surviving claims have been the subject of Myriad's recent
infringement lawsuits. See infra Part III.A.
" This claim related to a method for testing drug efficacy by growing a BRCA
cell with a deleterious mutation in the presence and absence of the drug. Myriad,
689 F.3d at 1336-37.
12 There has long been a dispute, for example, about whether Myriad or a team
in the United Kingdom first sequenced the BRCA 2 gene. See generally Myriad,
689 F.3d at 1348-49 (Bryson, J., dissenting) (discussing history of discovery of
BRCA genes); BRCA Briefing Page, DUKE INST. GENOME SC. & POL'Y,
http://www.genome. duke.edu/centers/cpg/Myriad/ (last visited Mar. 6, 2014).
13 35 U.S.C. § 102 (2012).
14 Id. § 103.
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requirement." Moreover, the invalidated gDNA claims were
Myriad's broadest and most powerful: they prevented anyone-
would-be competitors, researchers, or clinicians-from using
isolated genomic versions of the BRCA genes for any purpose
without Myriad's permission. Those that survive are narrower and
therefore, by definition, easier to work around. Finally, Myriad's
surviving patents begin to expire this year, and most will expire in
the next few years. 16 In sum, although it is true that from a claim-
counting perspective most of Myriad's portfolio is intact, that
portfolio is vulnerable, has been significantly narrowed in scope,
and has a limited life expectancy.
III. MYRIAD'S POST-MYRIAD OFFENSIVE
A. The Post-Myriad Lawsuits
Beginning in the summer of 2013, Myriad filed patent
infringement suits against a number of gene-testing competitors,
including Ambry, 17 Gene-by-Gene," Quest,19 Invitae,2 0 Labcorp,21
15 Id. § 112.
16 Patents issued on an application filed on or after June 8, 1995, expire twenty
years after the application date. Patents based on earlier applications expire on
the later of twenty years after the application date or seventeen years after the
date of issuance. See U.S. PATENT AND TRADEMARK OFFICE, MANUAL OF
PATENT EXAMINATION PROCEDURES § 2701 (citing 35 U.S.C. § 154 (2012)).
Applying these rules to some of the Myriad patents with surviving claims (all
raised in the recent Myriad infringement suits discussed infra Part III.A) yields
these expiration dates: Patent No. 5,709,999, June 7, 2015; Patent No.
5,747,282, June 7, 2015; Patent No. 5,753,441, January 5, 2016; Patent No.
6,051,379, December 2, 2017; and Patent No. 7,250,497, June 9, 2023 (an
outlier and the longest-lived of the patents involved in the recent litigation).
17 Complaint, Univ. of Utah Research Found. v. Ambry Genetics Corp., No.
2:13-cv-00640-RJS (D. Utah July 9, 2013). In each of the Myriad lawsuits, the
company is one of several plaintiffs, each of whom is an owner or co-owner of
one of the relevant patents.
1 Complaint, Univ. of Utah Research Found. v. Gene-by-Gene Ltd., No. 2:13-
cv-00643-EJF (D. Utah July 10, 2013).
19 Complaint, Univ. of Utah Research Found. v. Quest Diagnostics, Inc., No.
2:13-cv-0967-BSJ (D. Utah Oct. 22, 2013).
20 Complaint, Univ. of Utah Research Found. v. Invitae Corp., No. 2:13-CV-
01049-EJF (D. Utah Nov. 25, 2013).
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and GeneDx.2 2 All the cases have been filed in federal court in Salt
Lake City, Utah, where Myriad is based, and the complaints are
essentially the same, with some custom tailoring to the businesses
of the individual defendants. The first two, against the relatively
small companies Ambry and Gene-by-Gene, were immediately
consolidated; the Quest and GeneDx cases have recently been
consolidated with the original two.23 The Gene-by-Gene case was
settled in February 2014 on terms that have been characterized as
an unconditional surrender by the defendant.2 4 Gene-by-Gene
reportedly agreed to cease "selling or marketing" BRCA gene
tests, either on a stand-alone basis or as part of a broader panel,
although it did retain the right to offer whole genome or whole
exome testing, as well as certain "custom" products.2 5
In addition, Counsyl,2 6 which Myriad had not sued because it
has not started offering genetic tests, Quest,2 7 and Invitae2 8 all filed
21 Complaint, Univ. of Utah Research Found. v. Lab. Corp. of America
Holdings, No. 2:13-cv-01069-BCW (D. Utah Dec. 3, 2014).
22 Complaint, Univ. of Utah Research Found. v. GeneDx, Inc., No. 2:13-CV-
00954-TS (D. Utah Oct. 16, 2013).
23 The consolidations were ordered by the Judicial Panel on Multidistrict
Litigation under 28 U.S.C. § 1407. See Kevin E. Noonan, Panel on Multidistrict
Litigation Consolidates Myriad Cases in Utah District Court, PATENT DOCS
(Mar. 19, 2014), http://www.patentdocs.org/2014/03/panel-on-multidistrict-
litigation-consolidates-myriad-cases-in-utah-district-court.html. Section 1407
permits consolidation for purposes of pretrial proceedings only. 28 U.S.C. §
1407(a) (2012). However, given that these cases may turn on dispositive pretrial
motions (to dismiss or for summary judgment), the consolidation is more
significant than usual.
24 See Kevin E. Noonan, Gene-by-Gene Cries Uncle, Settles with Myriad
Genetics, PATENT DOCS (Feb. 7, 2014), http://www.patentdocs.org/2014/02/
gene-by-gene-cries-uncle-settles-with-myriad-genetics.html (reporting and analyzing
settlement).
25 Id.
26 Complaint, Counsyl, Inc. v. Myriad Genetics, Inc., No. 3:13-cv-04391-NC
(N.D. Cal. Sept. 20, 2013); see John M. Conley, Myriad Back in Court Again-
This Time as a Defendant, GENOMICS L. REP. (Oct. 8, 2013), http://www.
genomicslawreport.com/index.php/2013/10/08/myriad-back-in-court-again-this-
time-as-a-defendant/#more-13134 (analyzing declaratory judgment complaint).
27 Complaint, Quest Diagnostics Inc. v. Myriad Genetics, Inc., No. 13-cv-
1587 (C.D. Cal. Oct. 10, 2013).
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declaratory judgment actions in their respective home federal
courts in California. The Quest and Counsyl actions have been
consolidated with the other Myriad cases pending in Utah.2 9 The
three companies seek judgments (1) invalidating patents with
which Myriad has or is likely to threaten them and (2) declaring
that they are not infringing any Myriad patents that survive the
validity challenge. Declaratory judgments are a common tactic in
intellectual property disputes.3 0 A company that thinks it may be
sued for infringement-a prospective defendant, in other words-
jumps the gun and asks a court to rule in advance on the defenses it
would raise if it were sued for an infringement. By filing the
declaratory judgment action, the prospective defendant, now a
plaintiff, normally gets to choose both the time and the court that
will rule on these issues. These objectives have been frustrated by
the recent consolidation order in these cases, however, because the
critical pretrial issues will now be decided in the court that Myriad
chose.31
The suits against Ambry and Gene-by-Gene have progressed
the furthest, while the other cases are earlier in the pleading stage.
Myriad's complaints sought preliminary injunctions against Ambry
and Gene-by-Gene,3 2 and the defendants responded with antitrust
counterclaims alleging complex theories of actual and attempted
monopolization.3 3 Myriad's motions for preliminary injunctions
were extensively briefed and argued in the fall of 2013, and the
28 Complaint, Invitae Corp. v. Myriad Genetics, Inc., No. 3-13-cv-05495
(N.D. Cal. Nov. 26, 2013). Note that this case was filed the day after Myriad
sued Invitae in Utah. See supra note 20.
29 See Noonan, supra note 23.
30 See Lorelei Ritchie de Larena, Re-evaluating Declaratory Judgment
Jurisdiction in Intellectual Property Disputes, 83 IND. L. REV. 957, 959 (2008)
(noting that "[i]ntellectual property disputes are prime candidates for declaratory
relief").
31 See supra note 23 (discussing mechanics and significance of consolidation).
32 See Complaint, Univ. of Utah Research Found. v. Ambry Genetics Corp.,
supra note 17, at 15; Complaint, Univ. of Utah Research Found. v. Gene-by-
Gene Ltd., supra note 18, at 14 (requesting preliminary and permanent
injunctive relief in the respective cases).
33 See Conley, supra note 26.
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surviving motion against Ambry was denied on March 10, 2014, as
discussed below in more detail.3 4
Because the various infringement cases have a great deal in
common, it is instructive to take a closer look at those that have
progressed the furthest: Ambry and Gene-by-Gene (bearing in
mind that the latter has been settled). The defendants are two small
gene-testing companies that announced that they would offer
BRCA 1 and 2 tests almost immediately after the Supreme Court's
decision.35 Myriad has not, of course, sued on the gDNA claims
that the Supreme Court invalidated, nor on the method claims that
were rejected by the Federal Circuit in the part of the case that the
Supreme Court did not review.3 6 Instead, Myriad alleges that the
defendants' tests will infringe a number of other claims in ten
different patents that cover, among other things, cDNA (in
stretches as short as fifteen nucleotides), primers, and methods for
screening mutations and evaluating or diagnosing patients.37 They
are clearly everything-but-the-kitchen-sink complaints. Nonetheless,
many of the allegations seem plausible in the limited sense that the
claims asserted appear to cover (or "read on," in patent jargon)
what the defendants are probably doing or planning to do.
Ambry responded to Myriad's complaint not only by raising
the expected defenses of invalidity and non-infringement, but by
34 Univ. of Utah Research Found. v. Ambry Genetics Corp., No. 2:13-cv-
00640-RJS, 2014 WL 931057, at *55-56 (D. Utah Mar. 10, 2014).
3 See generally Kevin E. Noonan, Myriad Genetics Files Suit Against Ambry
Genetics for Genetic Diagnostic Testing ofBRCA Genes, PATENT DOCS (July 9,
2013), available at http://www.patentdocs.org/2013/07/myriad-genetics-files-
suit-against-ambry-genetics-for-genetic-diagnostic-testing-of-brca-genes.html;
Kevin E. Noonan, Myriad Genetics Files Infringement Suit Against Gene-by-
Gene for Genetic Diagnostic Testing of BRCA Genes, PATENT DOCS (July 9,
2013), available at http://www.patentdocs.org/2013/07/myriad-genetics-files-
infringement-suit-against-gene-by-gene-for-genetic-diagnostic-testing-of-brca-
.html (last visited Apr. 7, 2014) (reporting that both defendants had begun
competing with Myriad and analyzing the respective complaints).
36 See supra notes 5-8 and accompanying text.
3 See Complaint, Univ. of Utah Research Found. v. Ambry Genetics Corp.,
supra note 17, at 5-15 (asserting 10 claims for relief based on infringement of
various patents); Complaint, Univ. of Utah Research Found. v. Gene-by-Gene
Ltd., supra note 18, at 4-14 (asserting nine claims for relief based on
infringement of various patents).
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asserting a counterclaim under the Sherman Antitrust Act,3 8
charging Myriad with both attempted and actual monopolization of
the BRCA testing market.3 9 Ambry alleges that Myriad has gained
and maintained its market position through "exclusionary and
anticompetitive conduct" 40 that includes "bad faith enforcement of
its facially invalid patents." 4 1 Myriad then filed a motion to dismiss
the antitrust counterclaims. 42 Myriad argues that Ambry must show
that Myriad's patent infringement claims have been "objectively
baseless," and that Ambry cannot possibly carry that burden.43
In September and early October of 2013, the district court held
three days of hearings on Myriad's motion for a preliminary
injunction ("PI") ordering Ambry and Gene-By-Gene to cease
BRCA testing." As Judge Shelby recounted in his PI opinion, a
plaintiff bears a heavy burden in supporting a motion for a PI.45
That burden has four elements: (1) that the plaintiff is likely to
succeed on the merits; (2) that the plaintiff will suffer irreparable
harm if it does not get the PI; (3) that the balancing of the equities
favors the plaintiff; and (4) that the public interest favors the grant
of the PI. 46 Myriad persuaded Judge Shelby on issue (2) but failed
on issues (1) and (3), with issue (4) unclear. As a result, the PI was
denied. 47
38 Sherman Antitrust Act, 15 U.S.C. §§ 1-7.
39 Ambry's Counterclaims, Counts I & II, Univ. of Utah Research Found. v.
Ambry Genetics Corp., No. 2:13-cv-00640-RJS (D. Utah Aug. 5, 2013).
40 Id. at 66.
41 Id. at 65.
42 Plaintiff Myriad's Motion to Dismiss Antitrust Counterclaims, Univ. of
Utah Research Found. v. Ambry Genetics Corp., No. 2:13-cv-00640-RJS (D.
Utah Aug. 26, 2013).
43 Id. at 2.
" See Kevin E. Noonan, Preliminary Injunction in Myriad v. Ambry and
Gene-by-Gene: Myriad Replies, PATENT DOCS (Oct. 9, 2013), http://www.patent
docs.org/2013/10/preliminary-injunction-in-myriad-v-ambry-and-gene-by-gene-
myriad-replies.html (analyzing preliminary injunction proceedings).
45 Memorandum Decision and Order Denying Plaintiffs' Motion for
Preliminary Injunction at 55-56, Univ. of Utah Research Found. v. Anbry
Genetics Corp., No. 2:13-cv-00640-RJS (D. Utah Mar. 10, 2014).
46 Id.
4 71 Id. at 106.
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The major legal issue was Ambry's anticipated defense that the
patent claims Myriad is suing on are invalid. Ambry raised a range
of invalidity arguments: that Myriad's patents do not recite
patentable subject matter (Section 101), that they lack novelty
(Section 102), that they are obvious (Section 103), and that they
fail to satisfy the written description requirement (Section 112).48
The court based its decision solely on Section 101, finding the
other arguments redundant.4 9 Specifically, it found that Myriad
failed to show probability of success on the merits because Ambry
had raised a "substantial question" about the validity of the
relevant Myriad patent claims. 0
Judge Shelby grouped the Myriad claims into two categories:
"Primer Claims," which are product claims relating to single-
stranded DNA primers used in the polymerase chain reaction
("PCR") replication of BRCA 1 and 2 genes, and "Method
Claims" that cover screening BRCA genes for mutations by
comparing the sequences of patient samples with wild-type, or
normal, sequences. 1 The judge found that the Primer Claims might
not comprise patentable subject matter because they fell within
Myriad's rejection of claims on merely isolated DNA, even though
the primers in question are composed of cDNA, not gDNA.5 2 This
finding may be controversial on appeal, as the conventional
wisdom has been that the Supreme Court had barred patents only
on isolated gDNA.5 3 But Judge Shelby focused on two sentences in
the Myriad opinion in which the Supreme Court said: "cDNA is
4 8 Id. at 69.
4 9 1d. at 69-70.
'
0 Id. at 69.
Id. at 48-49.
5 2 Id. at 79-80.
53 See, e.g., Lyle Denniston, Opinion Recap: No Patent on Natural Gene
Work, SCOTUSBLOG (June 13, 2013), http://www.scotusblog.com/2013/06/
opinion-recap-no-patent-on-natural-gene-work/ ("The opinion conceded that
Myriad probably did create something when it synthesized DNA, in a form that
it called 'complementary DNA', or cDNA."). Such commentary on Myriad has
tended to focus on the Court's broad initial statement that "cDNA is patent
eligible because it is not naturally occurring," 133 S. Ct. at 2111, rather than the
subsequent subtle distinction that Judge Shelby relied on. See infra note 54 and
accompanying text.
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not a 'product of nature' and is patent-eligible under § 101, except
insofar as very short series of DNA may have no intervening
introns to remove when creating cDNA. In that situation, a short
strand of cDNA may be indistinguishable from natural DNA."5 4
Judge Shelby thought that the Myriad primers were just such
"short series of DNA," and hence likely to be patent-ineligible.
With respect to the Method Claims, Judge Shelby found them
indistinguishable from the claims rejected in the Supreme Court's
Mayo v. Prometheus" decision and the Federal Circuit's method
claims rulings in AMP, which were not reviewed by the Supreme
Court. Specifically, the judge held that "[a]side from the patent
ineligible, naturally occurring nucleotide sequence of the BRCAl
and BRCA2 genes, the other steps set forth in the Method Claims
are conventional activities that were well-understood and
uniformly employed by those working with DNA."5 6 That is, just
as the Mayo claims added only conventional medical activity to a
law of nature,57 the Method Claims add only conventional
interpretive activity to a product of nature. Thus, there was no
patentable subject matter in either case. Myriad has already
appealed the PI denial to the Federal Circuit.
54 Ambry, supra note 17, at 79 (emphasis added) (quoting Ass'n for Molecular
Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2119 (2013)).
" Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289
(2012).
56 Ambry, supra note 17, at 94.
5 7 Prometheus, 132 S. Ct. at 1298-1300.
See Kevin E. Noonan, Myriad Appeals Adverse Preliminary Injunction
Ruling, PATENT Docs (Mar. 20, 2014), http://www.patentdocs.org/2014/03/
myriad-appeals-adverse-preliminary-injunction-decision.html. A unique aspect
of an order granting or denying a PI is that, unlike almost all other pre-trial (or
"interlocutory") orders, it is immediately appealable. See 28 U.S.C. § 1292(a).
Rather than awaiting the end of the trial, which might be a year or more in the
future, Myriad took immediate advantage of this provision. As noted above,
Judge Shelby's reading of Myriad is likely to be controversial, and the Federal
Circuit judges might well disagree with it. Even if they do, however, the denial
of the PI could still be affirned because a lower court decision can be affirmed
on any ground that is discernible from the record, whether or not the lower court
relied on it. United States v. Am. Ry. Exp. Co., 265 U.S. 425, 435 (1924). Thus,
for example, the Federal Circuit might reverse on likelihood of success that is,
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Because the denial of Myriad's PI request is by definition
preliminary, it is difficult to prognosticate about the outcome of
this case, let alone to extrapolate to Myriad's other lawsuits.
Nonetheless, there are three further issues worth noting, albeit in a
speculative way.
First, Myriad has repeatedly emphasized in its filings against
Ambry and its public statements that the previous Federal Circuit
and Supreme Court litigation invalidated only 10 of the 520 claims
in its multi-patent portfolio.5 9 But now most of the rest of the
claims are squarely at issue, which means that the stakes for
Myriad in these cases are extremely high.
Second, Judge Shelby's PI ruling relied only on the threshold
issue of patentable subject matter, not addressing the question of
whether the challenged claims satisfy the other requirements for
patentability, including novelty and nonobviousness. He will have
to do so in the future, however, as Ambry has thrown the legal
kitchen sink at Myriad's patents, raising all potential objections to
validity.60 The novelty and obviousness challenges have serious
potential, and they should be watched carefully. There has long
been controversy over whether Myriad actually discovered the
BRCA genes, with competitors in both the United States and the
United Kingdom.6 1 With respect to obviousness, many in the
scientific community have claimed that Myriad did nothing more
than apply widely known techniques to a thoroughly studied
problem.62
Finally, what might one read into Gene-by-Gene's
capitulation? The surrender might reflect respect for the strength of
Myriad's position or be driven by the financial realities of a small
company waging a patent war against an adversary as rich and
likelihood of the patent claims proving invalid but still affirm the denial of the
PI on the basis of the balance of the harms.
59 See supra notes 8-10 and accompanying text; Plaintiff Myriad's Motion to
Dismiss Antitrust Counterclaims, supra note 42. Those 10 included gDNA
claims, which were the broadest and thus the most powerful of Myriad's claims.
60 Ambry's Answer at 29-30, Univ. of Utah Research Found. v. Ambry
Genetics Corp., No. 2:13-cv-00640-RJS (D. Utah Aug. 5, 2013).
61 See DuKE INST. GENOME SC. & POL'Y, supra note 12.
62 See id.
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aggressive as Myriad-or perhaps both. Outsiders simply cannot
know.
B. Tactical Considerations
Another set of questions is tactical. First, why did the
companies that Myriad has sued choose to jump into the BRCA
testing market right after the Supreme Court decision? The
question is especially compelling in the instances of Ambry and
Gene-by-Gene, which are far smaller than Myriad. The various
defendants had to be aware that Myriad has other patents that
would likely read on their respective testing activities. Given that,
there seem to be three hypotheses to explain their behavior: (1)
they did not believe that Myriad would sue them, given the
significant risks and disincentives it faced; 63 (2) they thought that if
they showed some willingness to fight, Myriad would back down
and settle (that is, license its patents) on acceptable terms; or (3)
they thought that Myriad's patents were vulnerable and were
prepared to spend a lot of money to invalidate them. Hypothesis
(1) has been disproved by events, as Myriad did choose to file suit.
Hypotheses (2) and (3) are related: defendants in any kind of
litigation, especially smaller defendants, usually get good
settlements only after they make a convincing showing that they
will fight and might win-and they rarely can get to that point
without spending significant money in the litigation. Here, the
defendants apparently thought that the war chests they had
accumulated were sufficient to get them to that point.
That leads to a related question: why did Myriad sue Ambry
and Gene by Gene, and then the other companies? An obvious
answer is to tell the market-loudly-that it is not ready to
concede its patent-based monopoly on BRCA testing. The first two
defendants, Ambry and Gene-by-Gene, who made splashy entries
moments after the Supreme Court ruled and might be vulnerable to
a war of attrition, presented themselves as inviting targets. It was
reasonable for Myriad to predict that they might not present
aggressive defenses or might settle quickly on terms favorable to
Myriad. The first of these predictions has been proven wrong in the
63 See infra notes 67-70 and accompanying text.
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Ambry case-Ambry has asserted massive counterclaims and has
fended off Myriad's P1 motion. The second has been borne out
with respect to Gene-by-Gene-it began by joining in Ambry's
counterclaims, but has subsequently settled without any apparent
concessions from Myriad.
A related issue is the downside risks that Myriad might have
foreseen. One possible risk is the public relations damage these
lawsuits continue to cause, with Myriad portrayed as a predatory
monopolist unconcerned about patients. 64 But all this was being
said before and immediately after the Supreme Court case, 65 So
Myriad probably concluded that the further damage to its image
would be marginal at worst. Moreover, there is no evidence that
bad publicity has hurt the company financially. 66
The real danger Myriad should have foreseen is that, as noted
above, many of these patent claims are vulnerable, and might be
invalidated if any of these cases proceeds to its conclusion. 67 Most
claims would probably survive patentable subject matter scrutiny,
although-as the Ambry PI order indicates-some might not,
including the short cDNA sequences and some of the method
claims. 68 But even those that survive the subject matter test would
64 For example, in July 2013 Sen. Patrick Leahy (D-Vt.), chairman of the
Senate Judiciary Committee that oversees patent policy, urged the National
Institutes of Health to "march in" under the Bayh-Dole Act and force Myriad to
license its patents. See Tony Dutra, Leahy Calls for NIH March-In Against
Myriad But Some Patents Not Subject to Bayh-Dole, BLOOMBERG LAW (July 19,
2013), http://about.bloomberglaw.com/law-reports/leahy-calls-for-nih-march-in-
against-myriad-but-some-patents-not-subject-to-bayh-dole/. Leahy's demand
generated considerable initial publicity but had no substantive effect, which
tends to validate Myriad's apparent lack of concern about bad publicity.
65 See, e.g., E. Richard Gold & Julia Carbone, Myriad Genetics: In the Eye of
the Policy Storm, 12 GENETICS MED. S39 (2010), available at http://www.
nature.com/gim/journal/v12/nls/full/gim2OlOl42a.pdf; Kevin E. Noonan,
Myriad Genetic Database Under Siege, PATENT DOCS (Apr. 15, 2013),
http://www.patentdocs.org/2013/04/myriad-genetic-database-under-siege.html
(citing "furious" reaction to Myriad's practices).
66 Myriad's stock did drop significantly in the immediate aftermath of the
denial of its PI motion against Ambry, but has recovered strongly. See supra
note 2 and accompanying text.
67 See supra notes 6-13 and accompanying text.
68 See supra notes 49-70 and accompanying text.
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still have to satisfy the more demanding novelty, nonobviousness,
and written description standards, and many of them might not.
Myriad probably thought that it had no choice but to sue.
Myriad had already seen that competitors were acting as if they
now could ignore its patents. Its confident, if not bellicose, post-
Supreme Court statements 69 had accomplished nothing. The only
escalation available was infringement litigation. Faced with a
choice between putting its patents at risk by suing and having them
ignored, it may have seemed an easy call: use 'em or lose 'em.
IV. MYRIAD'S PROPRIETARY DATA PLAN
To the accompaniment of much promotional fanfare, Myriad
opened a large new German testing lab in early 2012.70 Speaking
publicly (almost always a carefully orchestrated performance in a
publicly traded company), its executives emphasized that this was
just the beginning of a major European expansion.71 In response to
questions about its patents, which had previously been upheld but
considerably narrowed in Europe,7 Myriad had indicated that it
would rely on "other competitive advantages"-not patents-and
especially its ability to offer patients unparalleled speed and
accuracy.73 This claim was surely based on its vast and unique
interpretive database, derived from a patent-based U.S. testing
monopoly going back to the late 1990s and involving more than
one million patients.7 4 While the claims of competitive advantages
69 See supra note 9 and accompanying text.
70 See Myriad Genetics Opens Molecular Diagnostic Testing Lab in Munich,
Germany, BIO-M NEWS (Mar. 15, 2012), http://www.bio-m.org/en/news/myriad
-genetics-opens-molecular-diagnostic-testing-lab-in-munich-germany.html.
71 See id.
72 See Nayanah Siva, Myriad Wins BRCAl Row, 27 NATURE BIOTECHNOLOGY
8 (2009), http://www.nature.com/nbt/journal/v27/nl/full/nbtOlO9-8a.pdf.
7 John M. Conley, Dan Vorhaus & Robert Cook-Deegan, How Will Myriad
Respond to the Next Generation of BRCA Testing?, GENOMICS L. REP. (Mar. 1,
2011), http://www.genomicslawreport.com/index.php/2011/03/01/how-will-myriad-
respond-to-the-next-generation-of-brca-testing/ (quoting Myriad CEO Peter
Meldrum).
74 See Robert Cook-Deegan, John M. Conley, James P. Evans & Daniel
Vorhaus, The Next Controversy in Genetic Testing: Clinical Data as Trade
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related specifically to Europe, it is reasonable to assume that
Myriad will pursue a similar strategy in the United States when it
has finally lost its patent portfolio to expiration7 5 and further
invalidation.
A. The Variants of Unknown Significance Dilemma
Recent advances in genetic sequencing technologies are
generating vast amounts of genomic data that have the potential to
improve human health. However, genomic information is of little
worth to improving the health of individual patients if the medical
community cannot interpret this information. The clinical and
genomic data generated by large numbers of other patients is one
factor that allows doctors to assess the potential health risks facing
individual patients.7 6 Testing companies that collect genomic
information from numerous patients are able to determine the
clinical significance of genomic variants that may be unknown to
others.77 If a company retains such information as proprietary data,
a patient who needs to know the clinical significance of a
particular genomic variant may have no choice but to use the
services of that company.78 But patients, especially the
still-uninsured, may not have access to these companies or the
resources to afford their services.7 9
These realities lie at the core of Myriad's apparent business
plan as it expands its BRCA testing efforts in Europe. Most
Secrets?, 21 EUR. J. HUM. GENETICS 585, 585 (2013), http://www.nature.com/
ejhg/journal/v21/n6/full/ejhg2Ol2217a.pdf
7 See supra note 16 and accompanying text.
76 See generally John M. Conley, Adam K. Doerr & Daniel B. Vorhaus,
Enabling Responsible Public Genomics, 20 HEALTH MATRIX 325, 328-29
(2010) (describing necessity of integrating genotypic and phenotypic data).
7 See Cook-Deegan et al., supra note 74, at 585.
78 See id. at 586; Gina Kolata, DNA Project Aims to Make Public a
Company's Data on Cancer Genes, N.Y. TIMES, Apr. 12, 2013, http://www.ny
times.com/2013/04/13/health/dna-project-aims-to-make-companys-data-
public.html?pagewanted=all&_r-0.
79 See Tony Fong, US Senator Asks NIH's Collins to License Out Myriad's
BRCA 1/2 Gene Patents, GENOMEWEB DAILY NEWS (July 7, 2013), http://www.
genomeweb.com/clinical-genomics/us-senator-asks-nihs-collins-license-out-
myriads-brca-12-gene-patents (quoting Senator Patrick Leahy on cost barriers to
obtaining Myriad BRCA testing).
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patients who get BRCA testing have results that can be interpreted
in a relatively straightforward manner-either no variations from
the normal, or "wild type," harmless sequence variations or a
clearly deleterious mutation. 0 In a significant minority of tests,
however, mutations are difficult to interpret. 1 These are VUSs.
Myriad has claimed that the fraction of cases resulting in a VUS is
3% in its hands, versus 20% for its European competitors,8 2
although some experts think the 20% claim is far too high.8 3 This
discrepancy is due at least in part to Myriad's vast proprietary
database, which allows it to interpret ambiguous results that others
must relegate to the VUS category.8 4
Myriad has used its patent-based monopoly as the sole BRCA
1 and 2 test provider to develop, at its own cost, an extensive
database that relates VUSs to phenotypes, details the frequency of
VUSs in various populations, and includes genetic studies on
patient families." There is no comparable public database.8 6 To its
80 See Cook-Deegan et al., supra note 74, at 585.
8 See id.; Noonan, supra note 35.
82 See Noonan, supra note 35; Kolata, supra note 78. Myriad's most recent
claim is that its VUS rate is down to 2.1%. See J.M. Eggington et al., A
Comprehensive Laboratory-Based Program for Classification of Variants of
Uncertain Significance in Hereditary Cancer Genes, CLINICAL GENETICS, at 6
(Dec. 20, 2013), available at http://onlinelibrary.wiley.com/doi/10.1111/cge.
12315/abstract.
83 Indeed it must be, because Myriad's own 2013 paper notes that its VUS rate
was 12.8% in 2002, at a time when it was still reporting its data to public
databases. See Eggington et al., supra note 82, at 6. In informal discussions with
colleagues in the genetic medicine field, the authors have heard estimates for
competitors' VUS rates as low as 4%. In Judge Shelby's PI ruling, Ambry's rate
was reported to be 4.2%, based on affidavits from Ambry. Memorandum
Decision and Order Denying Plaintiffs' Motion for Preliminary Injunction at 64,
Univ. of Utah Research Found. v. Ambry Genetics Corp., No. 2:13-cv-00640-
RJS (D. Utah Mar. 10, 2014).
84 See Eggington et al., supra note 82, at 2.
8 See Cook-Deegan et al., supra note 74, at 585-86; Kolata, supra note 78
(estimating Myriad's investment at $500 million). Myriad estimates that $100
million of the $500 million it invested in BRCA testing, research, and
development was devoted to this database. See Benjamin Jackson, A Patient-
Centric Look at Gene Patents, IP WATCHDOG (May 9, 2013), http://www.ip
watchdog.com/2013/05/09/a-patient-centric-look-at-gene-patents-2/id=40119/.
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credit and the benefit of patients, Myriad has used its database to
reduce the frequency with which it reports a VUS.87 When Myriad
finds a new VUS-or one previously identified but whose clinical
significance is not yet understood-it offers free testing to the
patient's family members in an effort to help determine the
variant's significance." Myriad encourages the person with the
VUS to contact others in their family, providing a model letter that
patients can send their relatives.8 9 Myriad collects data regarding
the clinical outcome associated with that VUS, and a VUS may
ultimately be reclassified as deleterious or neutral as more is
learned; conversely, deleterious, or neutral mutations are
occasionally reclassified as VUSs. 90
Myriad essentially stopped contributing to public databases in
late 2004.91 Myriad scientists have published some papers since
then, but these typically describe Myriad's approach to "calling"
VUSs without listing gene sequences or detailing the company's
interpretive algorithms. 92 Myriad's proprietary approach led to a
"reprimand" by the policy committee of the European Society of
Human Genetics in late 2012.93
Note that data access is asymmetrical: Myriad has access to
public databases in interpreting mutations, but outsiders do not
have access to Myriad's database. 94 Even if all Myriad's patents
are invalidated, or new alternative testing technologies do not
infringe them, Myriad's patent-based competitive advantage will
persist. Until the requisite data and interpretive algorithms are
86 See Kolata, supra note 78 (reviewing early stages of efforts to create such a
public database).
87 See id.
See id. This is something that not all genetic testing laboratories do. See
Cook-Deegan et al., supra note 74, at 586.
89 See Cook-Deegan et al., supra note 74, at 586.
90 See id.
91 See id.; Kolata, supra note 78.
92 See, e.g., Eggington et al., supra note 82 (providing an example of the type
of Myriad publication described in the text).
93 See Emily Stehr, European Society ofHuman Genetics Reprimands Myriad
Genetics, BIOPOLITICAL TIMES (Nov. 7, 2012), http://www.biopoliticaltimes.
org/article.php?id=6495.
9 See Kolata, supra note 78.
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re-created in publicly accessible form, competing services will be
able to manage VUS results in only two ways: by having samples
analyzed at Myriad, or by rendering less adequate interpretations
based upon incomplete public data and algorithms. The former
perpetuates Myriad's exclusivity even after the expiration of its
patent rights,95 while the latter is unacceptable from a clinical
perspective.
B. Legal Strategy
If Myriad does pursue this data exclusivity strategy, the legal
approach should be straightforward: trade secret protection for its
database. Under the Uniform Trade Secrets Act ("UTSA")96 in
force in forty-seven U.S. states, 97 a trade secret can consist of any
kind of information that derives economic value from not being
generally known and is the subject of reasonable efforts to
maintain its secrecy. 98 Myriad's thus-far proprietary VUS data
would clearly satisfy this definition. The official commentary to
UTSA provides that "reasonable use of a trade secret including
controlled disclosure to employees and licensees is consistent with
the requirement of relative secrecy." 99 Myriad can easily satisfy
this requirement by imposing written duties of confidentiality on
its employees and any outsiders to whom it chooses to gain access,
and avoiding publication and contributions to public databases, as
it has done for the last ten years. 100 From an American legal
standpoint, Myriad's database is a medical version of the Coca-Cola
95 in other words, even when its patent-based legal monopoly over BRCA
testing has ended, Myriad's proprietary data base will still give it a de facto
monopoly over the interpretation of VUS test results.
96 NAT'L CONFERENCE COMM'R UNIF. STATE LAWS, UNIF. TRADE SECRETS
ACT WITH 1985 AMENDMENTS (1985), available at http://www. uniformlaws.
org/shared/docs/trade%/o20secrets/utsa final_85.pdf [hereinafter UTSA].
97 UNIF. LAW COMM'N, Trade Secrets Act, http://www.uniformlaws.org/Act.
aspx?title=Trade%20Secrets%2OAct (last visited Apr. 3, 2014). North Carolina,
not listed among the forty-seven, has a functionally similar statute. N.C. GEN.
STAT. §§ 66-152-157 (1981), available at http://www.ncga.state.nc.us/Enacted
Legislation/Statutes/HTML/ByArticle/Chapter 66/Article_24.html.
98 UTSA, supra note 96, § 1(4).
99 Id. § 1, cmt.
100 See supra notes 91 94 and accompanying text.
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formula, which has enjoyed trade secret protection since the late
1800s.101 One difference seems salient, however, in that Myriad's
data are about its customers' genomes, not the secret formula for a
soft drink.
The legal theory for protecting trade secrets is not as clearly
defined in Europe. According to a recent OECD report, 102 trade
secret protection in the United States is more robust than in any
other country in terms of the clarity of its definitions, the scope of
its coverage, and the efficacy of its remedies. 103 Nonetheless, on a
practical level, it is clear that Germany (where Myriad has
established its new lab) and other European countries would give
meaningful protection to Myriad's proprietary database under the
conditions described in the previous paragraph.104
Myriad, thus, has an effective legal regime for protecting its
proprietary database in the United States and Europe. A separate
question is whether regulatory authorities, public and private
payers, or others might have back-door ways to compel disclosure.
Part VI explores that issue after a discussion of ongoing third-party
efforts to replicate the Myriad database.
101 See Vault of the Secret Formula, WORLD OF COCA-COLA, http://www.
worldofcoca-cola.com/exhibits/vault-of-the-secret-formula/ (last visited Feb. 28,
2014); Kolata, supra note 78 (quoting critic of Myriad who said, "That works
for Coke, not for cancer").
102 Mark F. Schultz & Douglas C. Lippoldt, Approaches to Protection of
Undisclosed Information (Trade Secrets): Background Paper, OECD Trade
Policy Papers, no. 162 (2014), available at http://ideas.repec.org/p/oec/traaab/
162-en.html.
103 Id. at 32 (comparing protection across countries).
104 See id. One potentially material difference might be the ability to restrict
employees after their employment has ended. Id. at 99. A European Union
Directive also protects databases against some forms of copying, even if the
arrangement of the database is insufficiently original to qualify for copyright
protection. Directive 96/9/EC of the European Parliament and of the Council of
11 March 1996 on the Legal Protection of Databases, 1996 O.J. (L077),
available at http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:
31996L0009:EN:HTML.
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V. THIRD-PARTY EFFORTS TO REPLICATE MYRIAD'S DATABASE
A number of stakeholder groups have made efforts to promote
data sharing of genomic information. For example, the goal of
comprehensive initiatives like the National Human Genome
Research Institute's ("NHGRI") 1000 Genomes Project, The
Human Gene Mutation Database in Wales, MutaDATABASE, and
the Human Variome Project is to promote the creation of central
databases of shared data about genetic variants so that the medical
community can use this information to provide a "faster diagnosis,
more accurate prognosis and . . . better treatments .. ".. .o Other
public databases are specifically targeting BRCA 1 and 2 variants.
The Breast Cancer Information Core is maintained by the National
Human Genome Research Institute.106 Robert Nussbaum's Sharing
Clinical Reports Project ("SCRP") is contributing to public
databases such as ClinVar. 107 SCRP asks cancer clinicians to
contribute "limited," deidentified data on patients whose Myriad
test results showed a positive finding for a deleterious mutation.10
SCRP is representative of a nascent "Free the Data" movement,
currently centered on BRCA mutation data. 109 The Evidence-Based
Network for the Interpretation of Germline Mutant Alleles
("ENIGMA") started in 2009 and funded by the National Institutes
of Health is an interdisciplinary, international consortium of
clinicians and researchers that seeks to collect data and develop
10 THE HUMAN VARIOME PROJECT, PROJECT ROADMAP 2012-2016 6 (2012),
available at http://www.humanvariomeproject.org/index.php/publications/policy
-documents/207-project-roadmap-2012-2016; 1000 Genomes Project Consortium;
A Map of Human Genome Variation from Population-Scale Sequencing, 467
NATURE 1061 (2010); 1000 Genomes Project Consortium, An Integrated Map of
Genetic Variation from 1,092 Human Genomes, 491 NATURE 56 (2012).
106 Breast Cancer Information Core, NAT'L HUM. GENOME RES. INST.
http://research.nhgri.nih.gov/bic/ (last modified Nov. 10, 2013).
107 FREE THE DATA!!, SHARING CLINICAL REPS. PROJECT, http://sharing
clinicalreports.org/index.html (last visited Feb. 6, 2014); see also Kolata, supra
note 78.
10s How to Submit Data, SHARING CLINICAL REPS. PROJECT, http://sharing
clinicalreports.org/how-to-submit-data.html (last visited Mar. 20, 2014).
109 FREE THE DATA!!, SHARING CLINICAL REPS. PROJECT, supra note 107; see
infra notes 174-77 and accompanying text.
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analytical techniques "to assess the clinical significance of rare
unclassified sequence variants." 10
An obvious initial question is how long such initiatives will
take to catch up with Myriad. In an April 2013 interview,
Nussbaum, the SCRP leader, estimated that his project had
collected about 1,000 mutations, or about 1.5% of what Myriad has
collected.' ENIGMA claimed, in a 2012 article, to have collected
over 3,000 unique variants of the BRCA 1 and 2 genes. 112 Informal
estimates by experts in the field suggest that the various public
databases combined have replicated about 20-25% of Myriad's
data.113 A public alternative to Myriad is thus not immediately
forthcoming.
A related question concerns the quality of this alternative data.
For example, the SCRP data submission form calls only for the
gene name and test, result, and interpretation. 114 This is a far cry
from Myriad's compilation of health outcomes, family histories,
and other phenotypic factors. Part V.A pursues this practical
question of what kind of patient data needs to be shared. Then, Part
V.B considers the legal and ethical issue of protecting patient
privacy when sharing this information.
A. What Kind of Clinical Data Must Be Shared?
There is current debate in the field of genomics about what
kind of information needs to be collected and made available in
order to reliably translate research about genetic variants into
clinical practice. Some have pointed out that there is a lack of
standards for assessing the clinical significance of genetic
110 Amanda B. Spurdle et al., ENIGMA-Evidence-Based Network for the
Interpretation of Germline Mutant Alleles: An International Initiative to
Evaluate Risk and Clinical Significance Associated with Sequence Variation in
BRCAl and BRCA2 Genes, 33 HUM. MUTATION 2,5 (2012).
" See Kolata, supra note 78.
1 Spurdle et al., supra note 110, at 5 & Table 2.
113 These estimates have been provided to the authors in a number of
conversations.114 How to Submit Data, supra note 108.
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variants."' Others have noted that the "identification of genetic risk
prediction studies in public bibliographic databases is hindered by
inconsistencies in terminology" and that "there is a lack of key
information necessary to understand fully the studies, enable
comparison between them, and replicate and apply the prediction
models in other populations." 116 Yet others have emphasized the
importance of identifying "modifier genes and protective alleles,
which would titrate or counterbalance the risk of known
susceptibility markers . . . ."17 There have also been warnings that
environmental factors may play an important role in risk prediction
due to their impact on the epigenetic regulation of gene expression,
and, thus, must be taken into account when translating genetic
variant research into clinical practice."
The clinical significance of a genetic variant depends on
whether it is a predictor of poor health. 119 Determining whether a
genetic variant is a predictor of poor health requires access to data
from numerous individuals who have that particular genetic
115 See H. Duzkale et al., A Systematic Approach to Assessing the Clinical
Significance of Genetic Variants, 84 CLINICAL GENETICS 453, 459 (2013).
116 Adriana I. Iglesias et al., Scientific Reporting is Suboptimalfor Aspects that
Characterize Genetic Risk Prediction Studies: A Review of Published Articles
Based on the Genetic Risk Prediction Studies Statement, 67 J. CLINICAL
EPIDEMIOLOGY 1, 9 (forthcoming May 2014); see also A. Cecile J.W. Janssens
et al., Strengthening the Reporting of Genetic Risk Prediction Studies: The
GRIPS Statement, 8 PLOS MED. (2011), available at http://www.plosmedicine.
org/article/info%3Adoi%2F 10. 1371%2Fjournal.pmed. 1000420.
117 Eric J. Topol, Sarah S. Murray & Kelly A. Frazer, The Genomics Gold
Rush, 298 JAMA 218, 220 (2007).
"1 See, e.g., Teri A. Manolio, Bringing Genome-Wide Association Findings
into Clinical Use, 14 NATURE REVS. GENETICS 549, 551 (2013); Stephen B.
Manuck & Jeanne M. McCaffery, Gene-Environment Interaction, 65 ANN. REV.
PSYCHOL. 41, 60-61 (2014); Arturas Petronis, Epigenetics as a Unifying
Principle in the Aetiology of Complex Traits and Diseases, 465 NATURE 721
(2010).
H9 See Russell Harris, George F. Sawaya, Virginia A. Moyer & Ned Calonge,
Reconsidering the Criteria for Evaluating Proposed Screening Programs:
Reflectionsfrom 4 Current and Former Members of the U.S. Preventive Services
Task Force, 33 EPIDEMIOLOGIC REVS. 20, 23 (2011); C. Sue Richards et al.,
ACMG Recommendations for Standards for Interpretation and Reporting of
Sequence Variations: Revisions 2007, 10 GENETICS MED. 294, 295 (2008).
620 [VOL. 15: 597
Myriad After Mjriad
mutation. 12 0 If a sufficient number of individuals ("clinical data
subjects") with that mutation generally develop symptoms or
diseases, then there is evidence that the mutation is clinically
significant.12 1 Computational models also may be used to predict
the possible impact of a genomic variant, but these still ultimately
require access to information from clinical data subjects, and even
with such information, they are not able to make reliable final
determinations that can be used to guide patient care.122 As Hatice
Duzkale and colleagues have put it, computational models are
"useful in guiding classification, [but] they are not able to
determine or rule out pathogenicity."123
The field of genomics is in the middle of what some have
called a "gold rush"-a dash to identify as many clinically
significant genomic variants as possible in order to alert patients,
develop treatments, and prevent disease. 12 4 One of the ways this is
being achieved is through genome-wide association studies where
groups of patients with a particular disease are compared to groups
of healthy patients in order to determine what genomic variants
differentiate them.125 For example, a recent BRCA 1 genome-wide
association study identified novel genetic loci associated with risk
of breast and ovarian cancer. 12 6
The genomics gold rush is thus helping to identify numerous
genetic variants with potential clinical significance.127 The next
step is to learn to use this wealth of information in the care of
individual patients-to achieve "personalized medicine," or care
that is customized to a patient's genomic profile.128 Not every
120 See, e.g., Fergus J. Couch et al., Genome-Wide Association Study in
BRCAl Mutation Carriers Identifies Novel Loci Associated with Breast and
Ovarian Cancer Risk, 9 PLOS GENETICS (2013), available at http://www.plos
genetics.org/article/info%/ 3Adoi%/ 2F10.13710% 2Fjo urnal.pgen.1003212.
121 See id.
122 See Duzkale et al., supra note 115, at 459-62.
123 Id. at 462.
124 Topol et al., supra note 117.
125 See, e.g., Manolio, supra note 118, at 551.
126 Couch et al., supra note 120.
127 See Topol et al., supra note 117.
128 See Eric D. Green & Mark S. Guyer, Charting a Course for Genomic
Medicine from Base Pairs to Bedside, 470 NATURE 204, 209-11 (2011);
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patient who has a known "harmful" genetic variant will eventually
develop symptoms or disease. 12 9 In fact, a number of studies of the
genomics of healthy aging have shown that long-lived individuals
do not necessarily carry fewer genetic risk variants than the
average person.130 Some researchers hypothesize that these
individuals have longer and healthier lives because harmful
mutations are "buffered" by protective genes or environmental
factors.131
In the breast cancer context, the difficulty of translating general
tendencies into individually relevant recommendations means that
some of the women who are informed that they have an ostensibly
harmful BRCA 1 or BRCA 2 genetic variant will undergo
psychological harm, health care costs, and even medical
interventions, such as double mastectomy and bilateral
oophorectomy, which could all be unnecessary.132 In order to avoid
these unnecessary harms, researchers and laboratories will need to
collect and make available more clinical data that will help identify
protective factors.133 Some of these protective factors may have to
do with other genes that interact with the harmful genetic variant;
others may be environmental, such as diet, exercise, sleep, and
limited exposure to stress, childhood trauma, or tobacco smoke. 13 4
Margaret A. Hamburg & Francis S. Collins, The Path to Personalized Medicine,
363 N. ENG. J. MED. 301, 301 (2010).
129 See Hamburg & Collins, supra note 128, at 303.
130 See Angela R. Brooks-Wilson, Genetics of Healthy Aging and Longevity,
132 HuM. GENETICS 1323, 1330 (2013).
131 Id.
132 See Virginia A. Moyer, United States Preventive Servs. Task Force, Risk
Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer
in Women: U.S. Preventive Services Task Force Recommendation Statement,
160 ANNALS INTERNAL MED. 271 (2014); Isaac S. Kohane et al., The
Incidentalome: A Threat to Genomic Medicine, 296 JAMA 212, 212-15 n.2
(2006); Wylie Burke et al., Recommendations for Returning Genomic Incidental
Findings? We Need to Talk!, 15 GENETICS MED. 854, 856 n.11 (2013); Robert
Klitzman et al., Return of Secondary Genomic Findings vs Patient Autonomy,
310 JAMA 369, 369 n.4 (2013).
133 See Topol et al., supra note 117.
134 See Victoria K. Cortessis et al., Environmental Epigenetics: Prospects for
Studying Epigenetic Mediation of Exposure-Response Relationships, 131 HuM.
GENETICS 1565 (2012); Torsten Klengel et al., Allele-Specific FKBP5 DNA
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Therefore, the sharing of extensive patient personal information
may be necessary to develop dependable personalized genomic
risk prediction models that will help guide the care of individual
patients.
Moreover, emerging research suggests that these environmental
and genomic clinical data may be essential to accurately predict an
individual's genomic-based risks for some of the most harmful and
common diseases.135 Common diseases such as most types of
cardiovascular disease and cancer, schizophrenia, depression, and
diabetes, and widespread conditions such as obesity, are
considered complex diseases. 13 6 Complex diseases do not have a
single gene or genetic variant that is strongly predictive of the
disease, but rather have numerous genes that have a "relatively
small effect, but act in concert or with environmental influences to
lead to clinical disease."137
Therefore, in order to realize the promise of personalized
genomic medicine in the specific case of the BRCAl and 2 genes,
or more broadly, researchers and laboratories will need access to a
large amount of genomic and personal health information that can
help develop accurate genetic risk prediction models for individual
patients. However, sharing this clinical data would lead to major
concerns about patient privacy protection that must be addressed in
order to promote the sustainable growth of personalized
medicine.138
Demethylation Mediates Gene-Childhood Trauma Interactions, 16 NATURE
NEUROSCIENCE 33 n.1 (2013).
135 See supra notes 128-31 and accompanying text; Manuck, supra note 118,
at 60-61; Petronis, supra note 118, at 721; Randy L. Jirtle & Michael K.
Skinner, Environmental Epigenomics and Disease Susceptibility, 8 NATURE
REVS. GENETICS 253 (2007); A.M. Cressman & M. Piquette-Miller,
Epigenetics: A New Link Toward Understanding Human Disease and Drug
Response, 92 CLINICAL PHARMACOLOGY & THERAPEUTICS 669 n.6 (2012).
136 See Teri A. Manolio et al., A HapMap Harvest ofInsights Into the Genetics
of Common Disease, 118 J CLINICAL INVESTIGATION 1590 n.5 (2008); Robert
W. Schwenk et al., Genetic and Epigenetic Control of Metabolic Health, 2
MOLECULAR METABOLISM 337 n.4 (2013); Cortessis et al., supra note 134.
137 Manolio et al., supra note 136, at 1590.
138 Given the importance of genomic and clinical environmental data for
predicting health risks for some of the most common diseases, collecting this
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B. Sharing Genomic Data and Patient Privacy
The Institute of Medicine ("1M") recently stressed the
importance of transparency in the development of genomic-based
clinical technologies that are used to determine patient
management, emphasizing that tests must be reliable for different
kinds of populations. 13 9 To achieve this transparency, the IOM
recommended that developers of genomic-based technologies
should "[r]elease . .. data, code, and the fully specified computational
procedures." 14 0 Initiatives like the 1000 Genomes Project, Robert
Nussbaum's SCRP, and the Human Variome project also promote
clinical data-sharing in order to help advance personalized
genomic medicine. 14 1
Clinical data-sharing helps promote more reliable risk
prediction in clinical practice, which is ultimately beneficial to
every patient. 142  However, clinical data-sharing can also
compromise patient privacy. The IOM recognized this as a
potential obstacle to the development of reliable risk-prediction
testing, particularly when dealing with genetic data. 143 The Health
Insurance Portability and Accountability Act ("HIPAA") Privacy
Rule protects the privacy of individually identifiable patient health
information, also known as protected health information ("PHI"). 144
Genetic data is considered PHI under the HIPAA Privacy Rule. 145
The Privacy Rule only applies to covered entities such as
health plans, health care clearinghouses, and health care
information will also be of interest to medical biotechnology companies. In the
future, those companies that develop large data sets of environmental and
genomic data that have the potential to feed stronger predictive genomic risk
models for common diseases may want to protect them as trade secrets.
139 See INST. MED. ("IOM"), EVOLUTION OF TRANSLATIONAL OMICS: LESSONS
LEARNED AND THE PATH FORWARD (Christine M. Micheel et al., 2012).140 1d. at 51.
141 See 1000 Genomes Project Consortium, supra note 105; FREE THE
DA TA!!, SHARING CLINICAL REPS. PROJECT, supra note 107; THE HUM.
VARIOME PROJECT, supra note 105.
142 See Cook-Deegan et al., supra note 74; see also Manolio, supra note 118.
143 IOM, supra note 139, at 54.
144 45 C.F.R. § 160.103 (2013).
145 Modifications to the HIPAA Privacy, Security, Enforcement, and Breach
Notification Rules, 78 Fed. Reg. 5658, 5661 (Jan. 25, 2013).
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providers. 146 Researchers and entities such as genetic testing
companies, including direct-to-consumer genetic testing
companies, are generally not considered covered entities under
HIPAA. 147 However, if health care providers use a company's
genetic testing products, or if researchers want to obtain clinical
data from health care providers, the Privacy Rule would cover that
exchange of information. 148 Therefore, the Privacy Rule can be a
significant obstacle for clinical data-sharing in the development of
reliable genetic risk prediction tests.
Nevertheless, the Privacy Rule allows covered entities to share
PHI for research purposes if the patient provides authorization or if
the patient health information is de-identified. 149 De-identified PHI
is health-related information which "does not identify an individual
and with respect to which there is no reasonable basis to believe
that the information can be used to identify an individual . .1. 50
HIPAA lists a number of details that should be removed to help
ensure proper PHI de-identification. 1 These include names,
patient geographic information smaller than a state, the initial three
digits of the patient's zip code if the geographic unit contains
20,000 or fewer people, telephone numbers, social security
number, medical record numbers, and electronic mail addresses.152
Some might argue that de-identification is a relatively simple
and effective solution for clinical data-sharing in the context of
genetic risk prediction research and development.153 However, just
as genomic technologies have progressed immensely in the last
couple of years, so too has computer science. In fact, a recent
report published in Science described how the identities of subjects
whose "anonymous" genomic data was made available by the
NHGRI's 1000 Genomes Project were re-identified by using free
146 45 C.F.R. § 160.103.
147 Id.
148 Id.
14 9 1d. §§ 164.508, 164.514.
0 Id. § 164.514 (a).
1 Id. § 164.514 (b).
152 Id.
153 See Paul Ohm, Broken Promises of Privacy: Responding to the Surprising
Failure ofAnonymization, 57 UCLA L. REV. 1701, 1703-04 (2010).
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publicly available genealogical web sites and other public Internet
resources. 15 4 Even the identities of many of the participants'
relatives who had nothing to do with the 1000 Genomes Project
were found."' To make matters worse, even if no personally
identifiable data is purposely made available, privacy breaches and
illegal access to digital databases have become commonplace. 15 6
Some commentators argue that computer science has made it
so easy to re-identify information that at this point "[d]ata can be
either useful or perfectly anonymous but never both."157 As
mentioned above, the information required to develop reliable
personalized genomic risk prediction models could potentially
include not only genomic data, but also environmental clinical data
such as diet, exercise, sleep, exposure to stress, childhood trauma,
tobacco smoke, and other biomarkers.58 Given the personal nature
of such clinical data, attempts to sufficiently de-identify it would
often compromise its value for developing reliable individual
genomic risk prediction models.
There are some ongoing efforts to promote genomic clinical
data-sharing while minimizing patient privacy concerns. For
example, Robert Nussbaum's SCRP projectl5 9 asks providers and
154 See Melissa Gymrek et al., Identifying Personal Genomes by Surname
Inference, 339 SCIENCE 321, 323 24 (2013); see also Gina Kolata, Web Hunt
for DNA Sequences Leaves Privacy Compromised, N.Y. TIMES, Jan. 17, 2013,
http://www.nytimes.com/2013/01/18/health/search-of-dna-sequences-reveals-
full-identities.html; Greg Miller, Scientists Discover How to Identify People
From 'Anonymous' Genomes, WIRED (Jan. 17, 2013), http://www.wired.com/
wiredscience/2013/01/your-genome-could-reveal-your-identity/.
15 See Gymrek et al., supra note 154, at 323.
156 See Elizabeth A Harris et al., A Sneaky Path Into Target Customers'
Wallets, N.Y. TIMES (Jan. 17, 2014), http://www.nytimes.com/2014/01/18/busi
ness/a-sneaky-path-into-target-customers-wallets.html? r=0; Andres Jauregui,
Federal Reserve Confirms Security Breach, Calls Anonymous Hack Claim
'Overstated', HUFFINGTON POST (Feb. 5, 2013), http://www.huffingtonpost.com/
2013 /02/05/federal-reserve-security-breach n 2622698.html; Charlie Osborne,
The World's Biggest Data Breaches and Hacks of2013, ZDNET (Dec. 6, 2013),
http://www.zdnet.com/uk/the-worlds-biggest-data-breaches-and-hacks-of-2013-
7000023327/#photo.
157 Ohm, supra note 153, at 1704.
See supra notes 134-37 and accompanying text.
159 FREE THE DATA!!, SHARING CLINICAL REPS. PROJECT, supra note 107.
626 [VOL. 15: 597
Myriad After Mjriad
patients to submit the de-identified results of patients' BRCA 1 and
BRCA 2 tests in order to make available the interpretation of
genomic variants in the freely accessible public archive ClinVar. 160
SCRP minimizes concerns about patient privacy and violations of
the HIPAA Privacy Rule by asking patients and physicians to
submit copies of BRCA 1 and BRCA 2 laboratory results without
information that would identify the ordering physician, the patient,
or the laboratory that performed the test.16 1 The idea is to limit the
shared data to details such as test data, report data, genetic variants,
the interpretation of genetic variants, a description of the type of
analysis performed, and a description of the findings. 162 The
information requested is limited in such a way as to limit the threat
of patient re-identification and allow ordering physicians to submit
the reports without violating the HIPAA Privacy Rule. 163
Accordingly, on its "Frequently Asked Questions" page, SCRP
states, "[o]ur interpretation is that there are no [HIPAA]
restrictions on the use or disclosure of such de-identified health
information . ... "164 SCRP further claims that the project does not
require Institutional Review Board approval because it is clinical,
not research, and that no California state-law limits apply. 165
SCRP helps promote data-sharing, but its narrow scope is both
its principal strength and its greatest weakness. Collecting such
limited information may overcome patient privacy concerns and
thus encourage data submission, and it may help in developing a
general sense of the significance of particular genomic variants.
However, the lack of more detailed information about clinical data
subjects can make it difficult to contextualize the results and
160 Id.; Introduction-Clin Var, NCBI, https://www.ncbi.nlm.nih.gov/clinvar/
intro/ (last visited Feb. 7, 2014).
161 How to Submit Data, INT'L COLLABORATION CLINICAL GENOMICS, http://
www.iccg.org/about-the-iccg/collaborations/sharing-clinical-reports-project/
how-to-submit-data/ (last visited Feb. 7, 2014).
1 62 Id.
163 See Information for Clinicians, INT'L COLLABORATION CLINICAL GENOMICS,
http://sharingclinicalreports.org/infonmation-for-clinicians.html (last visited Feb.
7, 2014).
1 64 Id.
1 65 Id.
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extrapolate from the general findings to individual patients and
diverse populations.
Furthermore, even if a limited clinical data sharing approach
proves helpful for well-researched genes, such as BRCA 1 and
BRCA 2 that are relatively highly predictive of diseases, 16 6 it will
be much less useful for interpreting the clinical significance of
genomic variants in the multiple genes associated with complex
diseases. This is because with complex diseases, single genes
typically make only small individual contributions to disease risk,
particularly when compared to the contribution of environmental
factors. 167 Therefore, environmental information about clinical data
subjects may be essential for developing reliable personalized
inferences about the clinical significance of a genetic variant in
individual patients.
Looking forward, the problems associated with proprietary
clinical data, clinical data-sharing, and patient privacy are only just
beginning. Many believe that advances in genomics, along with
other developments in medical biotechnology, are giving rise to a
paradigm shift that will take health care from a reactive approach
to a proactive approach where medicine will be predictive,
preventive, personalized, and participatory ("P4 medicine"). 168
Champions of P4 medicine argue that "[i]n 10 years, everyone will
have his or her genome sequenced" and "a virtual cloud of billions
of data points will surround each patient." 16 9 Their idea is that
patients' genomes will be reviewed every year for new actionable
166 See Nancie Petrucelli et al., BRCAl and BRCA2 Hereditary Breast and
Ovarian Cancer, GENEREVIEWS, http://www.ncbi.nlm.nih.gov/books/NBK1247/
(last visited Feb. 28, 2014).
16 7 See Manolio, supra note 118, at 551.
168 See Andrea D. Weston & Leroy Hood, Systems Biology, Proteomics, and
the Future of Health Care: Toward Predictive, Preventive, and Personalized
Medicine, 3 J. PROTEOME RES. 179 (2004); Leroy Hood & Stephen H. Friend,
Predictive, Personalized, Preventive, Participatory (P4) Cancer Medicine, 8
NATURE REVS. CLINICAL ONCOLOGY 184 (2011). But see Eric T. Juengst et al.,
Personalized Genomic Medicine and the Rhetoric of Empowerment, 42
HASTINGS CTR. REP. 34 n.5 (2012).
169 Leroy Hood & Mauricio Flores, A Personal View on Systems Medicine and
the Emergence of Proactive P4 Medicine: Predictive, Personalized and
Participatory, 29 NEW BIOTECHNOLOGY 613, 614, 617 n.6 (2012).
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genetic variants. 17 0 In addition, biomarkers and environmental
factors such as diet, exercise, and sleep will be continuously
monitored through patient self-reporting and hand-held devices
"that can prick your finger, take a fraction of a droplet of blood and
quantify several thousand organ-specific proteins in five
minutes."171
Proponents of P4 medicine argue for the "'democratization' of
data-generation and data-analysis tools; that is, making these tools
accessible to all individual scientists so that they may carry out
either big science or small science projects."172 However, we have
seen this movie before: some call for data-sharing, some see an
opportunity to make a profit by treating clinical data as trade
secrets, others worry about the ethical, legal, and social
implications of both data-sharing and proprietary clinical data,
some do a little bit of each, and everyone says they want to
promote medical science for the benefit of the people. Who are the
heroes and who are the villains is anyone's guess, but
comprehensive public policy solutions must be crafted because
these problems are here to stay.
VI. WHAT CAN WE DO ABOUT IT? POLICY OPTIONS FOR
BUILDING A GENOMIC COMMONS
Policies to create incentives to share the data needed to
interpret the clinical and scientific meaning of genomic variation
are being proposed at several levels. Some policies address norms
and practices among clinicians and patients. Others center on
contributing data to databases from laboratories. Yet others focus
on product regulation through the Food and Drug Administration
(or equivalents in other countries). Finally, payers and health plans
could use their coverage and reimbursement policies to help build
a more robust evidence-based system of health care.
170 See id. at 617.
171 Id. at 617, 620.
172Id. at 615.
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A. Options for Patients and Clinicians Ordering Tests
The SCRP project focuses on clinicians and laboratories that
order tests for patients.173 The "Free the Data" movement, based at
the Genetic Alliance and supported by a coalition of organizations,
includes SCRP but is broader and also includes individual patients
who have received test results. 17 4 These are efforts to capture extant
data and channel them into public databases where they can inform
clinical interpretation of test results. A more recent variation is a
principled call for patients and health professionals to order tests
only from laboratories that share data with public databases, where
the data can inform clinical interpretation for future patients. The
Yale Genetic Testing Lab, for example, issued a statement on
February 24, 2014, that emphasizes open data access:
Whenever possible we will choose laboratories that have pledged to
make all of their past, present, and future gene data publicly available
in order to allow this important information to be freely accessible to
all clinicians and researchers, to further the advancement of medical
knowledge and to best serve patient care. We will not support
laboratories that hoard data.175
The European Society of Human Genetics issued a statement in
October 2012 that specifically chided Myriad for not sharing
clinically relevant information.176
These are actions that individual patients and health
professionals can take, but they are limited in that they are
voluntary and incomplete (SCRP and Free the Data) or mainly
hortatory rather than binding (exhortations and normative
statements). These efforts at the individual and clinical level
address the problem directly but lack the power of law and mainly
173 FREE THE DATA!!, SHARING CLINICAL REPS. PROJECT, supra note 107.
174 About Us, FREE THE DATA, http://www.free-the-data.org/about (last visited
Mar. 23, 2014).
175 Genetic Testing Position Statement, Cancer Genetic Counseling Program,
Yale Sch. of Med./Yale Cancer Ctr. (Feb. 2014), available at http://www.
docstoc.com/docs/167093854/Genetic% 2OTesting%/ 2OLab%/ 2OPosition%/o20Stat
ement.pdf.
176 Press Release, Eur. Soc'y Hum. Genetics, Privately Owned Genetic
Databases May Hinder Diagnosis and Bar the Way to the Arrival of
Personalised Medicine (Oct. 31, 2012), available at www.eshg.org/13.0.html.
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focus on the first step of data access, which is necessary but far
from sufficient.
B. Options for Testing Laboratories
In June 2013, the American Medical Association passed
Resolution 519 that calls for laboratories "to place all clinical
variants and the clinical data that was used to assess the clinical
variations that can impact the public's health."177 The ClinVar
database is undertaking a major effort to make it easy to contribute
data that have been vetted for clinical significance into a publicly
available database, and many laboratories have pledged to
participate.17 8 ClinVar lists those who submit data and the number
of genes and submissions each has contributed, an incentive based
on "credit for contribution." 17 9 ClinGen projects have been funded
to build pipelines for interpretation in a consistent way with
consensus standards.1 s0 They have also been working to develop
the requisite infrastructure. If these and other efforts to establish a
clinically useful database of clinically relevant genomic variants
(ClinVar) and methods to interpret those variants (ClinGen)
succeed, they will become the core of a "genomic commons" and a
reliable foundation for clinical use that is broadly available, thus
177 AM. MED. ASS'N, PROCEEDINGS OF THE 2013 ANNUAL MEETING OF THE
HOUSE OF DELEGATES 467 (2013), available at http://www.ama-assn.org/
assets/meeting/2013a/al3-resolutions.pdf [hereinafter AM. MED. ASS'N.]; see
also Policy D-460.971, AM. MED. ASS'N, https://ssl3.ama-assn.org/apps/ecomm/
PolicyFinderForm.pl?site=www.ama-assn.org&uri=%2famal%2fpub%2fupload
%2fmm%2fPolicyFinder%2fpolicyfiles%2fDIR%2fD-460.971.HTM (last visited
Apr. 1, 2014).
178 ClinVar Submissions, NAT'L CTR. FOR BIOTECH. INFO. (NCBI), https://
www.ncbi.nlm.nih.gov/clinvar/submitters/ (last visited March 23, 2014). Over
117 laboratories, institutions, and organizations have submitted data to ClinVar,
which is operated by the National Center for Biotechnology Information, U.S.
National Library of Medicine. This is still a small fraction of all potential
contributors. Id.
179 Id.
180 The ClinGen Resource, INT'L COLLABORATION FOR CLINICAL GENOMICS
(ICCG), http://www.iccg.org/about-the-iccg/clingen/ (last visited Mar. 23,
2014). ClinGen funded three projects that will channel data into the ClinVar
database. See FREE THE DATA!!, SHARING CLINICAL REPS. PROJECT, supra
note 107.
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supplanting the proprietary database model and indeed limiting its
value. These efforts are, however, nonbinding. They thus bring
together a coalition of the willing but do not address business
models incompatible with open and collaborative science.
Another policy option entails making data access and
independent verification of interpretation a criterion for laboratory
accreditation. Seeking accreditation is, by definition, voluntary-a
step down from formal regulation.' But accreditation is also often
linked to coverage and reimbursement.182 If data access and
verifiable interpretation become accreditation standards, then a
laboratory may be free to opt out, but some payers may not cover
or reimburse its tests. This was floated as an option at a February
3, 2013, Institute of Medicine workshop. 18 3 Participants noted that
the College of American Pathologists, an important accreditation
body for laboratory medicine, is considering data access and
verifiable interpretation among its laboratory standards. 18 4
C. Premarket Approval Regulation
At the next level of stringency, regulators and payers could
formally make data access and verifiable interpretation a condition
of approval for market through premarket approval of medical
devices. AMA Resolution 519 (June 2013) included a
recommendation to this effect, urging "payers, regulators and
providers to make clinical variant data and their interpretation
publicly available through a system that assures patient and
provider privacy."" The statutory authority for the FDA or its
non-U.S. equivalents to compel access to data and methods is a
subject of both discretion and debate.
18 See Eleanor D. Kinney, Private Accreditation as a Substitute for Direct
Government Regulation in Public Health Insurance Programs: When Is It
Appropriate?, 57 L. & CONTEMP. PROBS. 47, 49 (1994).
182 See id.
183 Assessing Genomic Sequencing Information for Health Care Decision
Making: A Workshop, INST. OF MED., http://www.iom.edu/Activities/ Research/
GenomicBasedResearch/2014-FEB-03.aspx (last visited Mar. 23, 2014).
18 See Discussion: Reimbursement Decisions, INST. OF MED. (Feb. 3, 2014),
http://www.iom.edu/~/media/Files/Activity%/ 20Files/Research/Geno
micBasedResearch/2014-FEB-03/AudioFiles/14%/o20Discussion.mp3.
185 AM. MED. Ass'N, supra note 177, at 467.
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The FDA is highly protective of proprietary data submitted for
the purposes of evaluating the safety and effectiveness of a
product.18 6 The agency generally requires the submitter's
authorization before releasing any proprietary data, and the
unauthorized release of proprietary data by any FDA employee is
considered a crime.187 On the one hand, this policy promotes
disclosure of important safety information to the FDA because
applicants have some level of assurance that they will maintain any
competitive advantage provided by their proprietary data.
However, this policy often conflicts with the FDA's responsibility
to advance "public health by . . . helping the public get the
accurate, science-based information they need to use medicines
and foods to maintain and improve their health."1 88
VUS data are essential to discerning the clinical significance of
genetic variants revealed by genetic tests. Therefore, independent
access and validation of this information is necessary for the safe
and effective use of genetic technologies. Pressure to improve the
disclosure of safety and effectiveness data for drugs and medical
devices led Congress to pass Section 801 of the Food and Drug
Administration Amendments Act ("FDAAA 801").189 This Section
mandates the report and public disclosure of clinical trial data for
drugs and medical devices regardless of source of funding. 190 The
results reporting requirements are relatively limited, but this
initiative promotes independent verification of results and safe and
effective use of medical devices. VUS data collected by genetic
testing companies in the course of their business generally will not
186 See PETER BARTON HUTT ET AL., FOOD AND DRUG LAW 1591 (Robert C.
Clark et al. eds., 3rd ed. 2007).
187 See 18 U.S.C. § 1905 (2012) (criminalizing disclosure of confidential
information); Christine D. Galbraith, Dying to Know: A Demand for Genuine
Public Access to Clinical Trial Results Data, 78 Miss. L.J. 705, 719 (2009)
(discussing the issue more broadly).
1I What We Do, FOOD & DRUG ADMIN., http://www.fda.gov/aboutfda/what
wedo/ (last visited Mar. 11, 2014).
189 Food and Drug Administration Amendments Act of 2007, Pub. L.
No. 110-85, 121 Stat. 424 (2007) [hereinafter FDAAA 801].
190 Id.; see also Tony Tse et al., Reporting "Basic Results" in
ClinicalTrials.gov, 136 CHEST 295 (2009).
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constitute a clinical trial for the purpose of FDAAA 801.191
However, withholding VUS data as trade secrets will foreseeably
result in unnecessary harms to patients because these data are
necessary to make appropriate decisions about patient
management. Therefore, the FDA should be provided the authority
to establish broader disclosure requirements that will allow it to
address the safety challenges of emerging genomic technologies.
D. Publication Standards
Robert Merton most famously articulated the features of
science that distinguish it from other human endeavors:
communalism, universalism, disinterestedness, and organized
skepticism. 192 These features drive the publication standards
applied by scientific journals, including the norm that publications
be based on transparent research supported by accessible data. The
furor over access to data arising in the February 2001 publications
of a draft human reference genome led to a National Research
Council report on publication standards that recommended rapid
access to data and underlying methods, the UPSIDE Principle:
Uniform Principle for Sharing Integral Data and Materials
Expeditiously. 193 Some journals, including the Proceedings of the
National Academy of Sciences, adopted the standard forthwith. 194
The centerpiece of the debate was another business model
surrounding another proprietary database, in this case, the human
reference sequence and related software developed by Celera,
which had raced with the public Human Genome Project to a
conclusion that was declared a tie in a June 2000 ceremony with
announcements in the White House and 10 Downing Street in
London. 195 Science editor Donald Kennedy's decision to publish
191 See FDAAA 801, supra note 189, §801(a)(1)(A)(ii).
192 Robert K. Merton, The Normative Structure ofScience, in THE SOCIOLOGY
OF SCIENCE: THEORETICAL AND EMPIRICAL INVESTIGATIONS 267-78 (1942).
193 Nat'l Res. Council, Sharing Publication-Related Data and Materials:
Responsibilities ofAuthorship in the Life Sciences (2003).
194 Nicholas R. Cozzarelli, UPSIDE: Uniform Principal for Sharing Integral
Data and Materials Expeditiously, 101 PROC. NAT'L ACAD. SCI. 3721, 3721-22
(2004).
195 Clinton and Blair Hail Gene 'Triumph', THE GUARDIAN (June 26, 2000),
http://www.theguardian.com/science/2000/jun/26/genetics13.
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the article from the Celera group was highly controversial, and so
the NRC study was commissioned to address the responsibilities
that accompanied publication in scientific and medical journals. 196
The debates about access to data and research transparency
have not entirely tamped down. The International Committee of
Medical Journal Editors has espoused a set of recommendations
for publication that has been regularly revised but emphasizes
access to data and research transparency. 197 Many of the principles
are subject to interpretation. The Eggington article cited above, for
example-which reports Myriad's 2.1 % rate of VUS results, down
from 12.8% in 2002-describes how Myriad conducts its
interpretation. 198 It does not show the underlying data, however,
nor report the list of variants in a way that allows replication.
Neither does it include interpretive algorithms nor models that
drive the interpretation and the numbers reported. There is no
reason to doubt Myriad's veracity, but there is equally little solid
evidence to meet the standards of reproducibility, and this article
clearly falls short of the ICJME and UPSIDE principles
recommended by the National Research Council. Yet this article
was published in a clinical journal in December 2013. Myriad was
not obligated to publish at all, and its description of VUS calling is
useful, but it is not independently verifiable or replicable. The
choice of publication outlet was presumably colored by the
journal's standard for comporting with scientific norms. For
example, the article clearly does not meet the standards recently
announced for Public Library of Science journals, 199 but Myriad
196 COMM. ON RESPONSIBILITIES OF AUTHORSHIP IN THE BIOLOGICAL SCIs.,
NAT'L RES. COUNCIL, NAT'L ACAD. SCIs., SHARING PUBLICATION-RELATED
DATA AND MATERIALS: RESPONSIBILITIES OF AUTHORSHIP IN THE LIFE
SCIENCES 17 (National Academies Press, 2003).
197 See Int'l Comm. of Med. J. Eds., Recommendations for the Conduct,
Reporting, Editing, and Publication of Scholarly Work in Medical Journals
(2013), available at www.icmje.org/icmje-recommendations.pdf.
198 Eggington et al., supra note 82, at 6.
199 Theo Bloom, Data Access for the Open Access Literature: PLoS's Data
Policy, PLOS, http://www.plos.org/data-access-for-the-open-access-literature-
ploss-data-policy/ (last modified Mar. 1, 2014). The basis for the presumption
that the Eggington paper would be rejected is the following criterion:
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nonetheless found a clinical journal willing to publish a descriptive
article without access to underlying data or methods. This
highlights two limitations of relying on publication practices to
ensure data access and verifiable interpretation: (1) publication is
voluntary, and (2) standards may be public, but they are variably
interpreted and implemented among journals and other
publications.
E. Coverage and Reimbursement
A final option, and one that would drive incentives through all
the previous steps, would be for payers (both public and private),
national health systems, and health plans that directly pay for
goods and services to incorporate criteria for data access and
verifiable interpretation into decisions about coverage and
reimbursement. The philosophy behind such a move is spelled out
in two recent National Academies reports, one centered on
"Omics,"200 and the other on laying a foundation for "Precision
Medicine." 20 1 Both reports note the central importance of access to
data and sharing of algorithms, models, and methods as bedrock
principles. They underscore the importance of replicating results in
science and the move toward "evidence based medicine" in
establishing clinical validity. Whether and how payers will begin
to take up such recommendations and implement them into
coverage and payment decisions will arguably be the most
powerful determinant of whether and to what degree open science
norms and practices drive adoption of genomic technologies.
[When] conclusions depend solely on the analysis of proprietary data
(e.g., data owned by commercial interests, or copyrighted data)
[manuscripts will not be considered]. If proprietary data are used, the
manuscript must include an analysis of public data that validates the
conclusions so others can reproduce the analysis and build on the
findings.
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VII. CONCLUSION
Myriad built a proprietary database out of its patent estate and
converted it into a source of competitive advantage. Myriad's
service monopoly for genetic testing of BRCA genes is an outlier
case in many respects. BRCA testing is far more common than
other genetic tests, and a blockbuster patent-dependent business
model made BRCA testing highly lucrative. The decision to stop
sharing data about genomic variants in 2004 did not attract
attention until the Myriad case drew attention to it. Few other
companies may be able to garner such market power via a patent
monopoly and then leverage that service monopoly into a
proprietary database conferring commercial advantage. The
situation may be rare. Or it may not be, depending on the nature of
proprietary databases that might proliferate as DNA sequencing
and other genomic technologies become ubiquitous.
Whether proprietary databases become a major systemic
problem for health services that demands policy change will
depend on whether a "genomic commons" will emerge to weaken
the commercial value of proprietary data strategies. The size,
stability, and utility of the genomic commons will in turn depend
on the degree to which data about and methods for interpreting the
clinical significance of genomic variants are shared. The extent of
such sharing will ultimately be determined by choices made by
individual patients, health professionals, testing laboratories,
regulatory bodies, and payers. The current controversy over
Myriad's proprietary database is an early and compelling case
study over whether a genomic commons can survive and thrive in
the current legal and policy environment.
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